MedPath

Anxiety and Symptom Burden in Hemodialysis Patients

Completed
Conditions
ESRD
Anxiety
Registration Number
NCT04143100
Lead Sponsor
The Rogosin Institute
Brief Summary

Anxiety has been identified as a prevalent and significant co-morbid condition in patients with End Stage Renal Disease (ESRD) being treated with hemodialysis. In particular, anxious sensitivity to symptoms commonly experienced by dialysis patients may lead patients to prematurely terminate their dialysis sessions and may have consequences on their dialysis adequacy and overall quality of life.

The proposed study will examine the relationships between anxiety, depression, quality of life, symptom burden and dialysis prescription adherence. The primary regression analyses will be used to predict the influence of anxiety and depression (independently and together) on measures of adherence behaviors.

Detailed Description

Additional analyses will examine the relationship of elevated anxiety and depression scores on symptom burden, QOL, and other measures of dialysis adherence. Retrospective data of the preceding three months will be used to calculate measures of dialysis adherence (shortening and skipping) and clinical parameters.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Receiving In-center hemodialysis
Exclusion Criteria
  • Non-English speaking

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Generalized Anxiety Disorder-7 (GAD-7)This is a cross-sectional study, with anxiety scores being correlated with previous 6 months of adherence data

Anxiety measure - higher scores indicate more anxiety

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Rogosin Institute

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath